USAID reinstates contracts for Georgia company that helps feed malnourished kids after Elon Musk responds to CNN reporting
Mark Moore, the founder MANA Nutrition, shared screenshots of the rescinded contract termination notifications with CNN.
'Thrilled,' he said in response to the news.
He also told CNN that he was working to quickly start using USAID-labeled pouches in production again: 'It's a yo-yo. I just texted the factory and told them to switch back to USAID packaging as of midnight.'
The development came after Elon Musk said on social media earlier on Sunday in response to CNN's previous reporting about the terminated USAID contracts that he would 'investigate' and 'fix it.' MANA's canceled contracts had been the result of the Trump administration's drastic efforts to slim down the federal government led by Musk, who leads a new government agency called the Department of Government Efficiency (DOGE).
Moore's company makes a special kind of peanut butter paste – a type of RUTF ('Ready-to-Use Therapeutic Foods') – that many humanitarian aid workers are familiar with. It is fortified with milk and essential vitamins, packed with calories and sent to severely malnourished children around the world, including some countries in Africa. USAID has historically supported and funded the development and distribution of RUTF products over the years.
On Wednesday afternoon, Moore got word from USAID that MANA's contracts with the agency were being canceled. CNN spoke with Moore just minutes after he said he received a series of contract termination letters from USAID. One of his first orders of business was asking his workers mid-production to immediately stop putting labels that say 'USAID' on the pouches that the peanut butter paste is squirted into.
He said without contracts with the agency, he would not be allowed to distribute any products bearing the agency's name.
The back-and-forth is just one of the many aftershocks of the Trump administration's rapid decimation of USAID, which has suffered more severely than almost any other agency across the government. Thousands of positions at the federal agency have been eliminated and the vast majority of its officials have been placed on leave. Contracts are being canceled left and right, leaving many in the humanitarian aid world reeling.
In normal times, Moore's plant produces 10 pouches of the lifesaving paste every second. Each small bag contains 500 calories' worth of the special peanut butter — which does not require refrigeration or additional preparation.
In their warehouse, Moore said last week, there were around 400,000 boxes of USAID-branded RUTF ready to be shipped out. He estimated that if USAID didn't pay MANA for those boxes, he would have at least $10 million in wasted peanut butter pouches on his hands. And that didn't include an additional $14 million in reimbursements from the federal government that he was already waiting for.
Erin Boyd, a USAID nutrition adviser who was laid off from the agency in January, told CNN it was not an overstatement to say that children would die as a result of the decimation of USAID and funding for RUTF.
'Even before this happened, there wasn't enough funding to treat all the children who were presenting wasting.' Boyd said.
Wasting, according to UNICEF, refers to a life-threatening form of malnutrition: 'Children with wasting are too thin and their immune systems are weak, leaving them vulnerable to developmental delays, disease and death,' the group says.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
AMD posts mixed Q2 results but offers better than expected Q3 outlook on AI sales
AMD (AMD) reported its second quarter results after the bell on Tuesday, missing on adjusted earnings per share (EPS), but beating analysts expectations on revenue. The company also provided better than anticipated Q3 guidance of between $8.4 billion and $9 billion. Wall Street was expecting $8.3 billion. The announcement comes ahead of rival and market leader Nvidia's (NVDA) own earnings report later this month. AMD stock was flat following the news. The company's shares are up 44% year to date and 29% over the last 12 months, while Nvidia shares are up 32% and 77%, respectively. For the quarter, AMD saw adj. EPS of $0.48 on revenue of $7.6 billion. Wall Street was expecting EPS of $0.49 on revenue of $7.4 billion, according to Bloomberg consensus estimates. AMD says it saw an $800 million impact from the Trump administration's ban on the sale of the company's MI308 AI chips to China. Nvidia took a $4.5 billion write-down from the ban in Q1 and said it expects a larger $8 billion hit in its second fiscal quarter. Trump reversed course on the ban last month, which should help make up for some of those losses in the coming quarters. AMD should also benefit from the launch of its MI350 line of AI chips, designed to go toe-to-toe with Nvidia's Blackwell-powered chips. According to AMD, the MI350 line, which includes the MI350X and MI355X, offers four times the AI compute performance and a 35x increase in inferencing capabilities versus its predecessors. AMD's Data Center segment revenue topped out at $3.2 billion, meeting Wall street expectations. The company saw $2.8 billion in the segment last year. Beyond the Data Center segment, AMD's Client business, which includes sales of CPUs for desktops and laptops, generated $3.6 billion in revenue versus an anticipated $2.5 billion. Email Daniel Howley at dhowley@ Follow him on X/Twitter at @DanielHowley. Sign in to access your portfolio
Yahoo
2 minutes ago
- Yahoo
Pfizer CEO shares 3 pillars of company's cost-cutting efforts
Pfizer (PFE) topped second quarter expectations, but looming Trump-era pharmaceutical tariffs remain a concern. Pfizer CEO Albert Bourla joins Market Domination to discuss the company's earnings results and cost-cutting efforts. He also notes that a manufacturing shift would require a grace period due to long timelines. To watch more expert insights and analysis on the latest market action, check out more Market Domination. Pfizer reporting a beat on revenue and earnings for its second quarter. But the pharmaceutical manufacturer is facing new hurdles with tariff threats and calls from President Trump to lower prices. Our own, Julie Hyman, and senior health reporter, Anjalee Khemlani, spoke with the CEO about cost-cutting efforts and the future of the firm. I would call it more its productivity enhancement and margin expansion. We do that by implementing three things. One, it is focus. So we stop doing things that they are not that important, and we double down on things that they are. The second is technology. Technology right now offers tremendous opportunities for improvement of productivity, particularly AI and simplification of our business process. There is a lot of waste that is happening when you have complicated structures that require usually more people than if you have streamlined your areas. And this is where we are. We have announced a program that we are on track to exceed actually this year. And then announced an additional 1.7 billions of cost reductions, 1.2 billions of that until '27 will happen in SGNA in administrative and marketing and selling expenses. And that will fall to the bottom line. 500 millions will happen in R&D, and that will be reinvested all back in R&D. So it's not just the cost-cutting though, obviously, investors also want to see growth on the top line, growth in revenues. You guys did have growth in revenues this quarter by 10%. And the revenue growth has been more volatile. So how do you keep that momentum going and also find stability? Yes. If you see the elements of our revenues, the volatile piece is mainly our COVID. Because COVID could happen in different quarters every year. Usually there are two waves every year and in sometimes like 23, one way, the summer or the winter are stronger. And the same as in 24. So it's a different year by year. So I think that's the variability. The rest of the business, it's a very strong, continuous growth momentum, I think, and new products and recently acquired products contributed 4.7 billion dollars in this first half of the year. And they are growing at 15%. So it's very solid. I do want to talk about the backdrop from Washington. Because that's something that involves, that affects not just you, but the whole industry. You're also currently the head of the Pharmaceutical Industry Association. You did say on the call that you have a special relationship with members of this administration. Of course, we've heard the president be critical of the industry. What do you feel you have been able to educate President Trump about to sort of better help him understand the industry's perspective? I said we have a special relation with the president because that relation was cemented during the COVID crisis. He was very concerned. He want to make sure that we speed up the development of vaccines. So we speak every second week. So he was very active and he would ask about studies and where we are, and what can we do to accelerate. So it was very, it was a bonding, let's say, exercise. No, I, I think he's educated. Of course, it doesn't go into the details, is not his job, but he understands the dynamics. I had multiple times the opportunity to discuss with him the impact that the middleman has in the prices in the US. And he understands this very well and he speaks very vocally about it. Other things that they are subsidizing, that they are taking out of the prices of pharma, so that the patient pays a lot, but then we don't collect all of that because it goes to other areas like 340B. So he, what he wants to achieve, it is to have a better deal. He's very competitive. He doesn't like that others paying less. And he wants to fix it and we are very productively discuss, productively discussing right now what we can do on that. And the president did say in an interview today that tariffs could eventually reach 250%. He's talking about a phase in of that. Are you confident that you'll avoid that outcome for the industry, that 250% on imports of pharmaceuticals? I don't want to speak for the president, but what he said today, which was very important also was that it will be a very small tariff in the first couple of years. And then he opened actually the window for a grace period. Because I had this discussion with him and I had this discussion with multiple other members of the administration, but a manufacturing site to be completed, it takes more than five years for our industry. We in North Carolina, we just completed, not just, but we completed recently a few years back, the build of one manufacturing site. But was one product only, and it took us four and a half years and that was our record. So you can't just say you need to do it immediately and pay tariffs until you transfer. We can't afford to pay tariffs and the investments to transfer. Right. Makes sense. I want to bring in our Anjalee Khemlani, who, of course, you also know, our senior health reporter to talk more about some of these issues. So Anj, I know you're also, of course, watching the pricing debate very closely. Yeah, that most favored nations clause. Albert, I love the letter. Got your special, you know, name crossed out on there from Trump. But going to the contents of it, I know you've already talked about the DTC push and getting that direct to consumer push. You've already unfolded a strategy there, so you're really ahead of the curve there. But I want to actually talk about the pricing part of it because we've had notes from analysts talking about how it's really unfeasible to do most favored nations pricing the way that it's laid out in that letter. Can you talk to us about how you're planning for that? We are planning for all different scenarios of different ways of implementing something like that. And we are discussing and making mitigation plans. But we don't know how that will end up. We are still discussing it with with the president, how and what will be the devil could be on the details in this case. And talking about the tariffs as well. I know that with the manufacturing push, the industry had been trying to really pull the president away from these tariffs and conversations around it with the more than $200 billion in investments. Explain to us how that works considering that 90% of prescription drugs are generics and those are the ones that are cheaper to make, come from overseas, have smaller margins. Therefore, not really appealing to companies like you to produce. Meanwhile, the branded drugs are mostly produced here with the API is coming from overseas. So can you just put it together for us on how it would really impact you with tariffs coming in? What components? Depends on the product and depends how the custom authorities define a country of origin. First of all, you are right that generics are more than nine prescriptions per 10 in the US. And those are the cheapest medicines anywhere in the world. The generic prices in the US are the cheapest of any medicine. I think again, patients are paying way more than the real price of the generics, because of ways that the insurance system and the benefits work. But even with that, they are the cheapest generics in the world. Then the 10% or less that they are, they're branded. Many of them are manufactured here, as you know, probably. We have 13 sites in the US of manufacturing. 11 are manufacturing plants and then two are gigantic warehouses, almost like a plant. So we do a lot of them here, but we over the years, we produce some stuff outside. And Ireland is a typical example, Switzerland is a typical example, other places are typical examples. And those we need to understand if they will be the API will dictate the country of origin or where the final product is made.
Yahoo
2 minutes ago
- Yahoo
DOJ set to seek hate crime charges in killing of Israeli Embassy staffers: Sources
The Justice Department is set to seek hate crime charges and the death penalty against the alleged gunman who fatally shot two Israeli embassy staffers in Washington, D.C., two sources familiar with the matter confirmed to ABC News Wednesday. Prosecutors are poised to request that a grand jury indict Elias Rodriguez, as soon as this week, sources said. He has remained in custody since the fatal shooting of Yaron Lischinsky and Sarah Milgrim outside the Capitol Jewish Museum on May 21. MORE: 2 Israeli Embassy staffers killed in 'act of terror' in Washington, DC CNN first reported news of the expected charges. Rodriguez was charged via criminal complaint with first-degree murder, murdering foreign officials and using a firearm to commit murder and a crime of violence, a day after the shooting. Interim D.C. U.S. Attorney Jeanine Pirro emphasized at the time that the charges were only initial in nature. "A young couple at the beginning of their life's journey, about to be engaged in another country, had their bodies removed in the cold of the night in a foreign city in a body bag. We are not going to tolerate that anymore," Pirro said during a press briefing on May 22. "Antisemitism will not be tolerated, especially in the nation's capital." Early last month, prosecutors in Rodriguez's case sought an extension for time to return an indictment against him, noting the complex and unusual nature of the charges he was facing. MORE: What to know about the suspect in the killing of a couple outside the Capital Jewish Museum Rodriguez was seen in videos shouting "Free, Free Palestine!" inside the museum just minutes after he allegedly shot Lischinsky and Milgrim dozens of times, and later allegedly told police upon his arrest, "I did it for Palestine." But to secure an indictment on the new charge that Rodriguez's acts amounted to a hate crime, prosecutors would need to have evidence that his alleged actions were motivated by antisemitism and not just hatred toward Israel and the war in Gaza. Rodriguez has not yet entered a plea in his case. A public defender representing him did not immediately respond to ABC News' request for comment. The complaint alleges that Rodriguez shot the couple in the back and then fired again at Milgrim as she tried to crawl away. Lischinsky, 30, was a researcher in the political department of the Israeli Embassy, while Milgrim, 26, organized U.S. missions to Israel.